Want to see TSE:BLAB full AI Analyst Report?
Top Page
Britannia Life Sciences Inc
(BLAB)
Select Model
Select Model
Rating:49Neutral
Price Target:
C$0.07
▲(0.00% Upside)
Action:Reiterated
Date:09/06/26
The score is held back primarily by weak and inconsistent operating performance (very small/declining revenue, negative core margins) and a recent turn to negative cash flow, despite a notably stronger low-leverage balance sheet. Technicals are mixed with longer-term downtrend signals, while valuation appears optically cheap on P/E but is less compelling given concerns about earnings quality.
Positive Factors
Very low leverage
Very low leverage reduces fixed financial obligations and gives the company greater flexibility to manage operating volatility. Compared with debt-to-equity ratios of roughly 3.0–3.8 in 2022–2024, the current capital structure provides a stronger base for funding operations and absorbing setbacks.
Negative Factors
Small and declining revenue base
A very small and shrinking revenue base limits operating scale, reduces the ability to absorb fixed costs, and makes results more vulnerable to individual contract or activity changes. Until revenue growth returns, the company has limited evidence of durable market traction or a stable platform for expansion.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage
Very low leverage reduces fixed financial obligations and gives the company greater flexibility to manage operating volatility. Compared with debt-to-equity ratios of roughly 3.0–3.8 in 2022–2024, the current capital structure provides a stronger base for funding operations and absorbing setbacks.
Read all positive factors
Britannia Life Sciences Inc (BLAB) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$11.36M
Dividend YieldN/A
Average Volume (3M)153.33K
Price to Earnings (P/E)0.8
Beta (1Y)-1.21
Revenue GrowthN/A
EPS GrowthN/A
CountryCA
Employees28
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.09
Shares Outstanding162,254,330
10 Day Avg. Volume19,307
30 Day Avg. Volume153,328
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.70
Price to Sales (P/S)30.75
P/FCF Ratio-12.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Britannia Life Sciences Inc Business Overview & Revenue Model
Company Description
Britannia Life Sciences Inc., headquartered in Toronto, Canada, offers specialized services in rigorous product evaluation, comprehensive safety analysis, and adherence to regulatory standards. The company supports businesses within the cosmetics,...
Britannia Life Sciences Inc Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
72
Positive
Cash Flow
34
Negative
| Breakdown | TTM | Jun 2025 | Mar 2025 | Jun 2023 | Jun 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 406.44K | 474.83K | 369.28K | 7.57M | 6.40M | 7.30M |
| Gross Profit | 30.00K | 38.86K | 27.33K | 4.85M | 4.64M | 5.26M |
| EBITDA | -1.07M | -1.39M | -4.39M | -1.90M | 6.95M | -10.77M |
| Net Income | 16.54M | 13.07M | 7.39M | -4.77M | 5.08M | -15.46M |
Balance Sheet | ||||||
| Total Assets | 24.84M | 23.87M | 11.61M | 22.26M | 23.55M | 21.09M |
| Cash, Cash Equivalents and Short-Term Investments | 12.41M | 17.14M | 7.85M | 1.32M | 2.60M | 1.63M |
| Total Debt | 211.52K | 229.14K | 1.86M | 7.29M | 8.41M | 5.19M |
| Total Liabilities | 2.79M | 3.12M | 5.31M | 15.59M | 12.49M | 15.61M |
| Stockholders Equity | 22.05M | 20.75M | 6.30M | 2.44M | 7.02M | 1.35M |
Cash Flow | ||||||
| Free Cash Flow | -665.64K | -1.16M | -2.62M | 1.75M | 874.41K | 2.71M |
| Operating Cash Flow | -665.65K | -1.16M | -2.62M | 2.09M | 1.22M | 2.80M |
| Investing Cash Flow | 6.04M | -5.25M | 11.27M | -1.44M | -3.32M | 653.95K |
| Financing Cash Flow | 34.44K | -110.77K | -2.17M | -1.97M | 2.95M | -2.58M |
Britannia Life Sciences Inc Technical Analysis
Neutral
0.07
Price Trends
0.07
Positive
0.08
Negative
0.08
Negative
Market Momentum
<0.01
Negative
55.31
Neutral
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BLAB, the sentiment is Neutral. The current price of 0.07 is above the 20-day moving average (MA) of 0.06, above the 50-day MA of 0.07, and below the 200-day MA of 0.08, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 55.31 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TSE:BLAB.
Britannia Life Sciences Inc Peers Comparison
UnderperformOutperform
Sector (51)
TSE:BLAB
Britannia Life Sciences Inc
0.07
<0.01
7.69%
TSE:HEM
Hemostemix
0.08
-0.05
-40.00%
TSE:IOT
Innovotech
0.08
-0.15
-65.91%
TSE:GLOW
Glow LifeTech
0.04
-0.02
-27.27%
TSE:TELI
Telescope Innovations Corp
0.51
0.15
41.67%
Britannia Life Sciences Inc Corporate Events
Business Operations and StrategyStock Buyback
Britannia Life Sciences Launches Share Buyback to Boost Long-Term Value
Positive
Aug 5, 2026
Britannia Life Sciences Inc. has launched a normal course issuer bid that will allow the company to repurchase and cancel up to 8,112,717 common shares, representing 5% of its issued and outstanding stock, over a 12‑month period starting Aug...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.